What is the recommended cephalexin dose and duration for a child with a staphylococcal skin or soft‑tissue infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pediatric Cephalexin Dosing for Staphylococcal Infections

For pediatric staphylococcal skin and soft tissue infections, administer cephalexin at 25-50 mg/kg/day divided into doses given every 6-12 hours for 5-7 days, with the specific frequency depending on infection severity and local MRSA prevalence.

Dosing Recommendations

Standard Dosing from FDA Label

The FDA-approved dosing for pediatric patients is 25-50 mg/kg/day in divided doses 1. For skin and skin structure infections specifically, this total daily dose may be divided and administered every 12 hours in children over 1 year of age 1.

Practical Dosing by Frequency

For twice-daily (BID) dosing:

  • Use 22-45 mg/kg/day divided BID for MSSA with MIC 1-2 mg/L
  • This achieves adequate pharmacodynamic targets in >90% of children 2
  • Improves compliance compared to QID dosing 3, 4

For three times daily (TID) dosing:

  • Use 15-25 mg/kg/day divided TID for standard MSSA infections 2
  • Validated in osteoarticular infections with 100% clinical cure rates 5

For four times daily (QID) dosing:

  • Reserve for severe infections or less susceptible organisms 1
  • May double the standard dose in severe infections 1

Critical Caveat: MRSA Prevalence

The most important clinical pitfall is that cephalexin has NO activity against MRSA, which now represents 87.8% of community-acquired S. aureus skin infections 6. However, for simple abscesses after incision and drainage, antibiotics may be unnecessary regardless—placebo achieved 90.5% cure versus 84.1% with cephalexin 6.

When to Use Cephalexin:

  • Only if local susceptibility data confirms MSSA
  • After culture results return showing methicillin-sensitive strains
  • In areas with low MRSA prevalence (<10-15%)

When NOT to Use Cephalexin:

  • Empiric therapy in areas with high MRSA prevalence
  • Necrotizing infections (requires IV therapy per IDSA guidelines 7)
  • Treatment failure after initial drainage

Treatment Duration

5-7 days of therapy is typically adequate for uncomplicated skin and soft tissue infections 8. Response should be evident within the first few days of treatment 8.

For β-hemolytic streptococcal infections (if co-infection suspected), extend treatment to at least 10 days 1.

Dosing Algorithm

  1. Confirm MSSA susceptibility (or high local prevalence of MSSA)
  2. Calculate total daily dose: 25-50 mg/kg/day based on severity
  3. Choose frequency:
    • BID dosing: Best for compliance, adequate for most infections
    • TID dosing: Alternative if concerned about coverage
    • QID dosing: Only for severe infections
  4. Duration: 5-7 days for skin/soft tissue; 10 days if streptococcal co-infection
  5. Reassess at 48-72 hours: If no improvement, consider MRSA coverage

Severe Infections Requiring Different Approach

For necrotizing fasciitis or deep tissue staphylococcal infections, the IDSA guidelines recommend IV therapy 7:

  • Nafcillin or oxacillin: 50 mg/kg/dose every 6 hours IV
  • Cefazolin: 33 mg/kg/dose every 8 hours IV
  • Vancomycin (if MRSA): 15 mg/kg/dose every 6 hours IV

Oral cephalexin is inappropriate for these life-threatening infections.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.